Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Macrogol + potassium chloride + sodium chloride + sodium bicarbonate is an osmotic laxative combination developed by AUG Pharma for the treatment of chronic constipation. The primary active component, macrogol (polyethylene glycol), is a high molecular weight polymer that remains in the gastrointestinal tract, where it binds water molecules through hydrogen bonding. This action increases the osmotic pressure and water content of the stool, leading to softened feces and increased bowel motility through the stimulation of peristalsis. The inclusion of electrolytes (sodium chloride, sodium bicarbonate, and potassium chloride) is intended to maintain isotonicity and prevent the depletion of essential salts or systemic fluid imbalances during the laxative process. This formulation is typically administered as an oral solution prepared from a powder.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on macrogol + potassium chloride + sodium chloride + sodium bicarbonate.